Navigation Links
Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil
Date:8/2/2011

MIAMI BEACH, Fla., Aug. 2, 2011 /PRNewswire/ -- Hair-growth developer Divine Skin Inc. (DSKX) introduced a new molecule, Nanoxidil, designed to stimulate follicles at the vertex of the scalp and surpass minoxidil for efficacy and tolerability. The innovative new compound offers unique advantages for penetration and persistence because its molecular weight is lower than that of minoxidil, a chemical on the market for 30 years now.

"This is a significant step forward in topical therapy, and we are very excited," said Daniel Khesin, CEO of Divine Skin.

He added that new products could be brought to market quickly since Nanoxidil did not require health-agency approval in most countries. He anticipated that Divine Skin would see significant revenue from Nanoxidil, which resulted from a five-year research-and-development effort.

Spectral.DNC-N, part of the DS Laboratories brand, would be the first treatment to employ Nanoxidil 5%, which could eventually succeed minoxidil as the new standard for topical treatment.

Nanoxidil's precise mechanism of action is still under study. Researchers expect it to potentiate desirable properties and mitigate side effects, compared to minoxidil. Studies of minoxidil have shown it to open ion channels, induce resting follicles into growth phase, increase follicle size, relax vascular smooth muscle, and stimulate vascular endothelial growth factor. Nanoxidil's lower molecular weight may boost its absorption properties for greater efficacy.

"We expect Nanoxidil to become a powerful force in the fight against thinning and shedding hair, working faster and better with enhanced tolerability," predicted Khesin. "It may allow more patients to maintain their hair, and it may work for patients who have not responded to standard minoxidil therapy."

About Divine Skin

Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.

DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through encapsulation (www.dslaboratories.com).

The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).

Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).

The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).

NutraOrigin blends nutritional supplements that address the health concerns expressed by consumers, including fatigue, headache, obesity, mobility, menopause, erectile dysfunction, and others. In clinical trials for the US government, its Omega line proved to enhance mental function (www.nutraorigin.com).

Contact:
Abner Silva
Investor Relations
Divine Skin Inc.
1.407.342.4112
investors@divineskin.com


'/>"/>
SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy
2. TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation
3. Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX)
4. FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
5. Summer Street Research Announces Expansion of Research Team with the Addition of Ling Wang, CFA, Senior Biotechnology Analyst
6. Industrial Biotechnology China News 1106
7. Phalanx Biotech Group Launches Rice Genome OneArray®
8. Axial Biotech Signs Agreement With Shriners Hospital for Children
9. Alacrita Asks "Are We All Biotech Now?"
10. Wound Management Technologies Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT
11. Reportlinker Adds White Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... York, NY (PRWEB) , ... January 24, 2017 ... ... (BMI), larger waist circumference, and increased serum leptin levels had a positive association ... The study published in the International Neurourology Journal involved 571 ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... available malaria Plasmodium falciparum culture panels with standard concentrations of histidine rich protein ... available in a range of concentrations from six different malaria strains, are intended ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences ... announced today that its orally active lead drug candidate, ... designation by the UK Medicines and Healthcare Products Regulatory ... A PIM designation is an early ... for the Early Access to Medicines Scheme ("EAMS"), intended ...
(Date:1/24/2017)... , ... January 23, 2017 , ... ... security, is the first-ever recipient of the National Academy of Sciences Prize in ... food security and nutrition. , The annual National Academy of Sciences (NAS) Prize ...
Breaking Biology Technology:
(Date:12/22/2016)... Calif. , Dec. 20, 2016  As part of ... 23andMe, the leading personal genetics company, recently released its latest ... . The book focuses on the topics of inheritance ... Generation Science Standards (NGSS) taught in elementary school classrooms in ... in a series by illustrator Ariana Killoran , whose ...
(Date:12/20/2016)... 20, 2016 The rising popularity of ... leasing is stoking significant interest in keyless access ... Bluetooth low energy (BLE), biometrics and near-field communication ... wave of wireless technologies in the automotive industry. ... advanced access systems opens the market to specialist ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):